Sudeep Pharma shares zoom 31% on listing above ₹593-IPO price

Sudeep Pharma shares debut on NSE, BSE. The ₹895-crore initial public offering witnessed overwhelming investor demand, closing with 93.71 times subscription on the final day.

Sudeep Pharma Ltd made an impressive market debut on Friday, listing with a sharp premium over its issue price following one of the most heavily subscribed IPOs.

The stock began trading at ₹733.95 on the BSE, a 23.7 per cent premium to the IPO price of ₹593. On the NSE, it opened at ₹730, reflecting a 23 per cent premium, setting a strong tone for its first day of trade.

Post-listing, the stock fluctuated between ₹725-₹777.25.

At 10.24 am, it traded at ₹766 and ₹766.70 on the BSE and NSE, respectively, 29 per cent above the offer price.

According to Shivani Nyati, Head of Wealth at Swastika Investmart Ltd., the listing strength is backed by its established presence in pharma and nutraceutical input materials, diversified product portfolio, long-term relationships with leading global pharma companies and strong export potential.

However, investors may remain watchful of margin sustainability, raw material price swings, and competitive intensity in specialty chemicals and pharma ingredients.

Nyati suggested investors allocated shares may consider booking partial gains, while aggressive long-term investors bullish on the specialty pharma ingredient space may hold the remaining portion with a disciplined stop-loss at ₹690.

Heavily subscribed ₹895 crore-IPO

The enthusiasm around the IPO was evident well before listing day. In the unlisted market, the stocks were commanding a 20.40 per cent premium, signalling strong demand from early investors, Nyati said.

The company’s ₹895-crore initial public offering witnessed overwhelming investor demand, closing with 93.71 times subscription on the final day. The response was particularly strong from institutional investors, with the QIBs category subscribed 213.08 times. Non-institutional investors subscribed 116.72 times, while the retail portion was booked 15.65 times.

Sudeep Pharma had earlier raised ₹268.5 crore from anchor investors. The price band for the offer was set at ₹563–593 per equity share. The IPO comprised a fresh issue of ₹95 crore and an offer-for-sale (OFS) of nearly 1.35 crore equity shares amounting to ₹800 crore by the promoters.

Sudeep Pharma, a technology-led manufacturer of excipients and speciality ingredients catering to the pharmaceutical, food, and nutrition sectors, has positioned itself as a key contributor to the global healthcare ecosystem. The company’s strong fundamentals, expanding product portfolio, and consistent industry demand were among the factors driving positive expectations for its listing.